BUDAPEST, April 24 /CNW/ - The weight loss medication Xenical
(orlistat 120mg) significantly reduces weight and improves
cardiovascular risk factors such as blood pressure, glycaemic
control and lipid profile in overweight and obese people with type
2 diabetes and hypertension, according to a study analysis
presented at the European Congress on Obesity (ECO), Budapest,
Hungary.(1)
This analysis strengthens the wealth of data already established
for Xenical that demonstrates that not only does it lead to
significant weight loss, it also has remarkable benefits in
reducing the risk of cardiovascular disease and diabetes, two of
the world's most serious health conditions. According to the World
Health Organisation (WHO), around 1.6 billion adults worldwide are
overweight, and at least 400 million adults are obese.(2) Excess
weight is associated with a number of life-threatening health
consequences, including:
- Cardiovascular disease - the world's number one cause of
death, killing 17 million people each year.(2) Hypertension is a
major risk factor for cardiovascular disease.(3)
- Diabetes - nine of every 10 people with type 2 diabetes are
overweight.(4) WHO projects that diabetes deaths will increase by
more than 50% worldwide in the next 10 years(5)
"We know that the incidence of type 2 diabetes and hypertension
rises steeply with increasing body weight," said Professor Iain
Broom, Department of Clinical Biochemistry and Metabolic Medicine,
Grampian University Hospitals NHS Trust, UK and study lead. "These
results support the use of Xenical to achieve substantial weight
loss, and to improve cardiovascular health and manage independent
risk factors in overweight and obese people." The study analysis
involved 2,692 overweight and obese people. Patients with high
cardiovascular risk (type 2 diabetes and hypertension), and treated
with Xenical vs. placebo demonstrated significant improvem
'"/>
Page: 1 2 3 4 5 6 Related medicine technology :1.
Arterial Plaque Significantly Reduced in Women Age 50-59 Taking
Hormones, Says New Analysis of Womens Health Initiative Data2.
Prexige Study Shows Significantly Less Impact on Blood Pressure
Than Ibuprofen in Osteoarthritis Patients with Controlled
Hypertension3.
Lumiracoxib Study Showed Significantly Less Impact on Blood
Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled
Hypertension4.
Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid
Arthritis Compared to a Current Standard of Care5.
Next Safety, Inc.s Innovative Drug Delivery System Will Replace
Cigarettes and Significantly Advance Pulmonary Medication Delivery6.
Ivivis PEMF Technology Significantly Improves Neuron Survival in
Parkinsons Disease Model, Study Finds7.
Mercks Investigational Migraine Treatment MK-0974 Significantly
Improved Migraine Pain on Several Efficacy Measures in a Phase II
Study8.
The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved
Progression Free Survival When Given Before and After Surgery in
Patients With Resectable Liver Metastases From Colorectal Cancer9.
Nexavar Significantly Extends Overall Survival by 44% in Liver
Cancer Patients10.
MabThera Significantly Extends Survival And Cures More Patients
With Aggressive Lymphoma Than Chemotherapy Alone11.
Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology
Shown to Significantly Lower Instances of Severe Retinopathy of
Prematurity in Extremely Low Birth Weight Infants